Condition 1: corona virus or COVID-19. Condition 2: COVID 19 ,virus not identified. COVID-19, virus identified COVID-19, virus not identified
Conditions
Interventions
Intervention 1: Intervention group: Inhaled Formoterol? In this group along with the standard regiment according to the national guideline of treatment for COVID-19, patients will take Formoterol 1 P
Sponsors
National Research Institute of Tuberculosis and Lung Diseases
Medochemie KSN
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: (COVID-19) with according to the clinical manifestations confirmed with CBC, CRP, and Chest radiography or other lab tests Patients who voluntarily sign our consent form.
Exclusion criteria
Exclusion criteria: Pregnancy Comorbidity Saturation less than 93% The presence of symptoms for more than 7 days History of formoterol intolerance cardiac diseases, such as heart failure or arrhythmia Recent history of using inhaled corticosteroids, bronchodilators, and ACE inhibitors Asthma or COPD Heavy Smoker
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Level of Improvement. Timepoint: the 5th and 10th days. Method of measurement: clinical evaluation, observation, physical examination, and call interview for follow up. | — |
Secondary
| Measure | Time frame |
|---|---|
| Total time to improvement. Timepoint: up to 30 days follow-up. Method of measurement: observation. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactFariba Ghorbani
National Research Institute of Tuberculosis and Lung Diseases
Outcome results
None listed